The short version of REV-ERB fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-01. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Additional effects included feeling stoned, alcohol-like intoxication, drifting of thoughts, and difficulty concentrating and cognitive impairment. The effects of the drug were described as highly dependent on set and setting, with prominent negative reactions in unfavorable environments or with too high of doses, including unpleasantness, anxiety, paranoia, social withdrawal, and unwillingness to take the drug again, among others. Physical effects of DET included DMT-like vegetative or autonomic symptoms, pupil dilation, sweating, slight burning and numbness of hands and feet, dizziness, vertigo, feeling sick, paleness, shakiness, muscle tremors, athetoid movements, vomiting, feeling of hollowness in the chest, pronounced tachycardia, pressor effects, and other somatic symptoms. Subsequent-day effects included an afterglow, hangover, lassitude, and cognitive fuzziness.
Reticular opacities, often associated with traction bronchiectasis Honeycombing manifested as cluster cystic airspaces, typically of comparable diameters (3–10 mm (0.12–0.39 in)) but occasionally large. Usually sub-pleural and characterized by well-defined walls and disposed in at least two lines. Generally one line of cysts is not sufficient to define honeycombing Ground-glass opacities are common but less extensive than the reticulation Distribution characteristically basal and peripheral though often patchy.
== Structure == NADK2 differs from other NAD kinases by containing an additional structural insert that alters its assembly. While most NAD kinases form tetramers, NADK2 exists as a stable homodimer. As a result, its activity remains relatively constant and does not increase upon oligomerization, unlike other NAD kinases.
=== New Jersey === Because streptomycin was isolated from a microbe discovered on New Jersey soil, and because of its activity against tuberculosis and Gram negative organisms, and in recognition of both the microbe and the antibiotic in the history of New Jersey, S. griseus was nominated as the Official New Jersey state microbe. The draft legislation was submitted by Senator Sam Thompson (R-12) in May 2017 as bill S3190 and Assemblywoman Annette Quijano (D-20) in June 2017 as bill A31900. The bill was passed on 2018-01-08 The bill designates Streptomyces griseus as New Jersey State Microbe (New Jersey Senate Bill 3190 (2017). Governor Phil Murphy signed the bill making it official in 2019.
Sources: en.wikipedia.org
==== French Polynesia ==== In French Polynesia, glass noodles are known as vermicelle de soja and were introduced to the islands by Hakka agricultural workers during the 19th century. They are most often used in maʻa tinito, a dish made with glass noodles mixed together with pork, beans, and cooked vegetables.
CoA-glutathione + NADPH + H+ The 3 substrates of this enzyme are CoA, glutathione, and NADP+, whereas its 3 products are CoA-glutathione, NADPH, and H+. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is glutathione:NADP+ oxidoreductase (CoA-acylating). Other names in common use include coenzyme A glutathione disulfide reductase, NADPH-dependent coenzyme A-SS-glutathione reductase, coenzyme A disulfide-glutathione reductase, and NADPH:CoA-glutathione oxidoreductase. This enzyme participates in cysteine metabolism. It employs one cofactor, FAD.
== Current status == Many exogenous agents have been developed since the discovery of 5-HT2C receptors. Thus far a small number of agonists, with sufficient selectivity for the 5-HT2C receptors over the other subtypes have been studied in clinical trials. A variety of other 5-HT2C receptor agonists remain in preclinical development, including Ro60-0175, WAY-163,909, and the inverse agonist SB-243,213. Evidence supports a therapeutic potential of 5-HT2C receptor modulation in the treatment of a variety of pathological conditions, including schizophrenia, obesity, urinary incontinence and sexual dysfunction.
Sources: en.wikipedia.org
=== Construction of the bicyclic core === Myers and co-workers have pioneered the application of transannular anionic cyclization reactions in the synthesis of the 5,9-fused bicyclic core of kedarcidin chromophore and neocarzinostatin chromophore. In the first incarnation, hydride delivery to a cyclic tetrayne was guided by aluminum coordination to a proximal alkoxide, thus generating the desired enediyne core in one step via two successive 5-exo-dig–type cyclizations. Later-generation syntheses of the core intercept this cascade cyclization, relying on lithium-halogen exchange on a cyclic vinyl bromide to generate the vinyl anion precursor to the bicyclic product.
Also, to bring the buildings up to the District of Columbia's current building code, the buildings required new plumbing, new electrical, HVAC, water, and fire suppression systems, new accessibility features for the disabled (including in one elevator), and the renovation has found higher levels of asbestos and a higher water table than was expected while also finding lead contamination in the ground underneath the buildings (which was not anticipated). Powell and the Federal Reserve have denied that the building designs included dining rooms or elevators for use only by VIPs or Federal Reserve Governors, rooftop terraces, and have asserted that the only proposed water features that had been included in the initial renovation plan for the East Building were eliminated. Additionally, both the East Building and the Eccles Building are included in the District of Columbia Inventory of Historic Sites while the East Building is also included in the National Register of Historic Places, and some of the cost overruns are due to changes to the design plans to comply with historic preservation laws for maintaining historic buildings and their appearance. The Eccles Building and East Building are also located on the National Mall, and the District's building code has a height restriction that requires that buildings not be taller than the United States Capitol, which required underground construction to expand one of the buildings to include a basement and an addition to the other for greater office space.
The mole (symbol mol) is a unit of measurement, the base unit in the International System of Units (SI) for amount of substance. One mole is an aggregate of exactly 6.02214076×1023 elementary entities which can be atoms, molecules, ions, ion pairs, or other particles. This number of entities equals 602,214,076,000,000,000,000,000, approximately 602 sextillion or 602 billion multiplied by one trillion. The number of particles in a mole is the Avogadro number (symbol N0) and the numerical value of the Avogadro constant (symbol NA) has units of mol−1. The relationship between the mole, Avogadro number, and Avogadro constant can be expressed in the following equation:
Forklifts as a pulley to raise and lower their fork carriage Chainsaws as cutting chains, which superficially resemble roller chains but are more closely related to the leaf chain. They are driven by projecting drive links which also serve to locate the chain onto the bar.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.